Nektar Therapeutics (NKTR) — SEC Filings

Overview

Nektar Therapeutics (NKTR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 20, 2026: On April 20, 2026, Nektar Therapeutics filed an 8-K report detailing events under Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The filing includes various exhibits, such as iXBRL data and graphical representations, but does not contain specific financial figures or

Sentiment Summary

Across 48 filings, the sentiment breakdown is: 3 bearish, 45 neutral. The dominant filing sentiment for Nektar Therapeutics is neutral.

Filing Type Overview

Nektar Therapeutics (NKTR) has filed 30 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13G, 4 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (48)

• Nektar Therapeutics Files 8-K with Exhibits — 8-K · Apr 20, 2026 Risk: low
  On April 20, 2026, Nektar Therapeutics filed an 8-K report detailing events under Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
• Nektar Therapeutics Files 8-K — 8-K · Dec 16, 2025 Risk: low
  Nektar Therapeutics filed an 8-K on December 16, 2025, to report on various events. The filing includes information related to Regulation FD disclosures, other
• 8-K Filing — 8-K · Nov 21, 2025
• Nektar Therapeutics Files 8-K — 8-K · Nov 10, 2025 Risk: low
  Nektar Therapeutics filed an 8-K on November 10, 2025, reporting events as of November 8, 2025. The filing primarily concerns Regulation FD disclosures, other e
• Nektar's Revenue Halves Amid Product Sales Halt, Net Loss Widens — 10-Q · Nov 7, 2025 Risk: high
  NEKTAR THERAPEUTICS reported a significant decline in total revenue for the nine months ended September 30, 2025, dropping to $33.425 million from $69.252 milli
• Nektar Therapeutics Files 8-K on Financials — 8-K · Nov 6, 2025 Risk: low
  Nektar Therapeutics filed an 8-K on November 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements a
• 8-K Filing — 8-K · Sep 18, 2025
• Nektar's Q2 Loss Widens Amid Revenue Dip, Raises $85M in Offerings — 10-Q · Aug 8, 2025 Risk: high
  NEKTAR THERAPEUTICS reported a net loss of $59.5 million for the quarter ended June 30, 2025, a significant increase from the $48.3 million net loss in the prio
• Nektar Therapeutics Files 8-K on Financials — 8-K · Aug 7, 2025 Risk: low
  Nektar Therapeutics filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition, and including financial statements and exhib
• Nektar Therapeutics Files 8-K with Material Agreement — 8-K · Jul 1, 2025 Risk: medium
  On June 30, 2025, Nektar Therapeutics entered into a material definitive agreement. The company also reported other events and filed financial statements and ex
• Nektar Therapeutics Sells U.S. Royalty Rights for $400M — 8-K · Jun 27, 2025 Risk: medium
  Nektar Therapeutics announced on June 27, 2025, that it has entered into a definitive agreement to sell its U.S. royalty rights for the drug Rezdiffra to an aff
• Nektar Therapeutics Files 8-K Report — 8-K · Jun 24, 2025 Risk: low
  On June 24, 2025, Nektar Therapeutics filed an 8-K report. The filing primarily concerns Regulation FD Disclosure, Other Events, and Financial Statements and Ex
• Nektar Therapeutics Files 8-K — 8-K · Jun 6, 2025 Risk: low
  Nektar Therapeutics filed an 8-K on June 6, 2025, reporting amendments to its articles of incorporation or bylaws and filing financial statements and exhibits.
• Nektar Therapeutics Files 8-K — 8-K · Jun 4, 2025 Risk: low
  Nektar Therapeutics filed an 8-K on June 4, 2025, reporting an "Other Event." The filing does not contain specific details about the event itself, but it is a s
• Nektar Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · May 28, 2025 Risk: low
  Nektar Therapeutics filed an 8-K on May 28, 2025, reporting on matters submitted to a vote of security holders as of May 23, 2025. The filing details the compan
• Nektar Therapeutics Files Q1 2025 10-Q — 10-Q · May 9, 2025 Risk: medium
  Nektar Therapeutics filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates. Key agreements mentio
• Nektar Therapeutics Files 8-K on Financials — 8-K · May 8, 2025 Risk: low
  Nektar Therapeutics filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and ex
• Nektar Therapeutics Files 2025 Proxy Statement — DEF 14A · Apr 25, 2025 Risk: low
  Nektar Therapeutics filed its definitive proxy statement (DEF 14A) on April 25, 2025, for its annual meeting scheduled for May 23, 2025. The filing outlines the
• Nektar Therapeutics Faces Delisting Concerns — 8-K · Apr 4, 2025 Risk: high
  Nektar Therapeutics filed an 8-K on April 4, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the earliest
• Nektar Therapeutics Files 8-K for Material Agreement — 8-K · Mar 28, 2025 Risk: medium
  Nektar Therapeutics filed an 8-K on March 28, 2025, reporting a material definitive agreement. The filing does not disclose specific details of the agreement, t
• Nektar Therapeutics Files 2024 10-K — 10-K · Mar 14, 2025 Risk: medium
  Nektar Therapeutics filed its 10-K for the fiscal year ending December 31, 2024, reporting on its operations and financial condition. The company, headquartered
• Nektar Therapeutics Files 8-K on Financials — 8-K · Mar 12, 2025 Risk: low
  Nektar Therapeutics filed an 8-K on March 12, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and
• Nektar Therapeutics Files 8-K Report — 8-K · Feb 24, 2025 Risk: low
  On February 24, 2025, Nektar Therapeutics filed an 8-K report to disclose other events and financial statements. The filing does not contain specific financial
• Nektar Therapeutics Files 8-K — 8-K · Feb 4, 2025 Risk: low
  Nektar Therapeutics filed an 8-K on February 4, 2025, reporting other events and financial statements. The filing does not contain specific details on new mater
• Nektar Therapeutics Files 8-K on Asset Acquisition/Disposition — 8-K · Dec 2, 2024 Risk: medium
  Nektar Therapeutics filed an 8-K on December 2, 2024, reporting the completion of an acquisition or disposition of assets. The filing also includes financial st
• SC 13G Filing — SC 13G · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• Nektar Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 8, 2024 Risk: medium
  Nektar Therapeutics filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quar
• Nektar Therapeutics Files 8-K — 8-K · Nov 7, 2024 Risk: low
  Nektar Therapeutics filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition, and including financial statements and exh
• Nektar Therapeutics Files 8-K: Material Agreement, Financials — 8-K · Nov 4, 2024 Risk: medium
  Nektar Therapeutics filed an 8-K on November 4, 2024, reporting on events that occurred on November 1, 2024. The filing indicates a material definitive agreemen
• SC 13G Filing — SC 13G · Oct 22, 2024
• Nektar Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 9, 2024 Risk: medium
  Nektar Therapeutics filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter.
• Nektar Therapeutics Files 8-K on Financials — 8-K · Aug 8, 2024 Risk: low
  Nektar Therapeutics filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and
• Nektar Therapeutics Files 8-K on Shareholder Vote — 8-K · Jun 6, 2024 Risk: low
  Nektar Therapeutics filed an 8-K on June 6, 2024, reporting on matters submitted to a vote of security holders on June 5, 2024. The filing does not contain spec
• Nektar Therapeutics Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: medium
  NEKTAR THERAPEUTICS (NKTR) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Nektar Therapeutics filed a 10-Q report for the period ending March 31,
• Nektar Therapeutics Files 8-K on Financials — 8-K · May 9, 2024 Risk: medium
  Nektar Therapeutics filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and ex
• Nektar Therapeutics Announces 2024 Annual Meeting of Stockholders on June 5 — DEF 14A · Apr 26, 2024 Risk: low
  NEKTAR THERAPEUTICS (NKTR) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Nektar Therapeutics will hold its 2024 Annual Meeting of Stockholde
• Nektar Sells Movantik Rights for Up to $100M — 8-K · Apr 17, 2024 Risk: medium
  Nektar Therapeutics announced on April 17, 2024, that it has entered into a definitive agreement to sell its U.S. royalty rights for the blockbuster drug Movant
• SC 13G Filing — SC 13G · Mar 15, 2024
• Nektar Therapeutics Files 2023 Annual Report on Form 10-K — 10-K · Mar 5, 2024 Risk: medium
  NEKTAR THERAPEUTICS (NKTR) filed a Annual Report (10-K) with the SEC on March 5, 2024. Nektar Therapeutics filed its 10-K report for the fiscal year ending Dece
• Nektar Sells Rezvoglar Rights for $10M Upfront — 8-K · Mar 4, 2024 Risk: medium
  Nektar Therapeutics announced on March 4, 2024, that it has entered into a definitive agreement to sell its U.S. commercial rights for the drug rezvoglar to a t
• Nektar Therapeutics Files 8-K with Material Agreement — 8-K · Mar 4, 2024 Risk: medium
  Nektar Therapeutics announced on March 4, 2024, that it entered into a Material Definitive Agreement. The company also disclosed unregistered sales of equity se
• Nektar Therapeutics Terminates Material Agreement — 8-K · Feb 16, 2024 Risk: medium
  Nektar Therapeutics filed an 8-K on February 16, 2024, reporting the termination of a material definitive agreement, effective February 12, 2024. The filing ind
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Vanguard Group Amends Nektar Therapeutics Stake — SC 13G/A · Feb 13, 2024 Risk: low
  The Vanguard Group, a major investment firm, filed an amended SC 13G/A on February 13, 2024, disclosing its ownership of Nektar Therapeutics' Common Stock as of
• NEKTAR THERAPEUTICS Files 8-K on Financial Condition, Reg FD — 8-K · Jan 10, 2024
  NEKTAR THERAPEUTICS filed an 8-K on January 10, 2024, to report on its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure'. This fili

Related Companies

BMY

Frequently Asked Questions